

Product datasheet for **RC217151L3V**

ELOVL7 (NM_024930) Human Tagged ORF Clone Lentiviral Particle

Product data:

Product Type:	Lentiviral Particles
Product Name:	ELOVL7 (NM_024930) Human Tagged ORF Clone Lentiviral Particle
Symbol:	ELOVL7
Mammalian Cell Selection:	Puromycin
Vector:	pLenti-C-Myc-DDK-P2A-Puro (PS100092)
Tag:	Myc-DDK
ACCN:	NM_024930
ORF Size:	843 bp
ORF Nucleotide Sequence:	The ORF insert of this clone is exactly the same as(RC217151).
OTI Disclaimer:	The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info
OTI Annotation:	This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene.
RefSeq:	NM_024930.1
RefSeq Size:	3815 bp
RefSeq ORF:	846 bp
Locus ID:	79993
UniProt ID:	A1L3X0
Cytogenetics:	5q12.1
Protein Families:	Transmembrane
MW:	33.2 kDa



[View online »](#)

Gene Summary:

Catalyzes the first and rate-limiting reaction of the four reactions that constitute the long-chain fatty acids elongation cycle. This endoplasmic reticulum-bound enzymatic process allows the addition of 2 carbons to the chain of long- and very long-chain fatty acids (VLCFAs) per cycle. Condensing enzyme with higher activity toward C18 acyl-CoAs, especially C18:3(n-3) acyl-CoAs and C18:3(n-6)-CoAs. Also active toward C20:4-, C18:0-, C18:1-, C18:2- and C16:0-CoAs, and weakly toward C20:0-CoA. Little or no activity toward C22:0-, C24:0-, or C26:0-CoAs. May participate in the production of saturated and polyunsaturated VLCFAs of different chain lengths that are involved in multiple biological processes as precursors of membrane lipids and lipid mediators.[UniProtKB/Swiss-Prot Function]